BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Nishizawa T, Suzuki H, Maekawa T, Harada N, Toyokawa T, Kuwai T, Ohara M, Suzuki T, Kawanishi M, Noguchi K, Yoshio T, Katsushima S, Tsuruta H, Masuda E, Tanaka M, Katayama S, Kawamura N, Nishizawa Y, Hibi T, Takahashi M. Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World J Gastroenterol 2012; 18(21): 2735-2738 [PMID: 22690086 DOI: 10.3748/wjg.v18.i21.2735]
URL: https://www.wjgnet.com/1007-9327/full/v18/i21/2735.htm
Number Citing Articles
1
Anthony O'Connor, Javier Molina‐Infante, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori Infection 2013Helicobacter 2013; 18(s1): 58 doi: 10.1111/hel.12075
2
Sheila López-Góngora, Ignasi Puig, Xavier Calvet, Albert Villoria, Mireia Baylina, Neus Muñoz, Jordi Sanchez-Delgado, David Suarez, Victor García-Hernando, Javier P. Gisbert. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment forHelicobacter pyloriinfectionJournal of Antimicrobial Chemotherapy 2015; 70(9): 2447 doi: 10.1093/jac/dkv155
3
Toshihiro Nishizawa, Takama Maekawa, Noriko Watanabe, Naohiko Harada, Yasuo Hosoda, Masahiro Yoshinaga, Toshiyuki Yoshio, Hajime Ohta, Syuuji Inoue, Tatsuya Toyokawa, Haruhiro Yamashita, Hiroki Saito, Toshio Kuwai, Shunsuke Katayama, Eiji Masuda, Hideharu Miyabayashi, Toshio Kimura, Yuko Nishizawa, Masahiko Takahashi, Hidekazu Suzuki. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori EradicationJournal of Clinical Gastroenterology 2015; 49(6): 468 doi: 10.1097/MCG.0000000000000165
4
Ju Yup Lee, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jung Won Lee, Dong Ho Lee. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018Helicobacter 2019; 24(6) doi: 10.1111/hel.12660
5
György Miklós Buzás. Helicobacter pylori – 2012Orvosi Hetilap 2012; 153(36): 1407 doi: 10.1556/OH.2012.29443
6
Toshihiro Nishizawa, Kosuke Sakitani, Hidekazu Suzuki, Shuntaro Yoshida, Yosuke Kataoka, Yousuke Nakai, Hirotoshi Ebinuma, Takanori Kanai, Osamu Toyoshima, Kazuhiko Koike. Clinical features of cardiac nodularity-like appearance induced by <i>Helicobacter pylori</i> infectionWorld Journal of Gastroenterology 2020; 26(35): 5354-5361 doi: 10.3748/wjg.v26.i35.5354
7
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima. Effects of patient age and choice of antisecretory agent on success of eradication therapy for <i>Helicobacter pylori</i> infectionJournal of Clinical Biochemistry and Nutrition 2017; 60(3): 208 doi: 10.3164/jcbn.16-86
8
Jason Ferreira, Steven F. Moss. Current Paradigm and Future Directions for Treatment of Helicobacter pylori InfectionCurrent Treatment Options in Gastroenterology 2014; 12(4): 373 doi: 10.1007/s11938-014-0027-6
9
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treatJournal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
10
Toshihiro Nishizawa, Hidekazu Suzuki, Masahiko Takahashi, Masayuki Suzuki, Toshifumi Hibi. Delay of second‐line eradication therapy for Helicobacter pylori can increase eradication failureJournal of Gastroenterology and Hepatology 2013; 28(10): 1608 doi: 10.1111/jgh.12281
11
Toshihiro Nishizawa, Hidekazu Suzuki. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testingFrontiers in Molecular Biosciences 2014; 1 doi: 10.3389/fmolb.2014.00019
12
Hideki Mori, Hidekazu Suzuki, Juntaro Matsuzaki, Hitoshi Tsugawa, Seiichiro Fukuhara, Sawako Miyoshi, Kenro Hirata, Takashi Seino, Misako Matsushita, Tatsuhiro Masaoka, Takanori Kanai. Efficacy of 10‐day Sitafloxacin‐Containing Third‐Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA MutationHelicobacter 2016; 21(4): 286 doi: 10.1111/hel.12286
13
Osamu Toyoshima, Toshihiro Nishizawa, Kazuhiko Koike. Endoscopic Kyoto classification of <i>Helicobacter pylori</i> infection and gastric cancer risk diagnosisWorld Journal of Gastroenterology 2020; 26(5): 466-477 doi: 10.3748/wjg.v26.i5.466
14
Miao Duan, Jing Liu, Xiuli Zuo. Dual therapy for Helicobacter pylori infectionChinese Medical Journal 2023;  doi: 10.1097/CM9.0000000000002565
15
Takahisa Furuta, Mihoko Yamade, Tomohiro Higuchi, Satoru Takahashi, Natsuki Ishida, Shinya Tani, Satoshi Tamura, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pyloriJournal of Clinical Medicine 2023; 12(9): 3110 doi: 10.3390/jcm12093110
16
Toshihiro Nishizawa, Munkhbayar Munkjargal, Hirotoshi Ebinuma, Osamu Toyoshima, Hidekazu Suzuki. Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic ReviewJournal of Clinical Medicine 2021; 10(12): 2722 doi: 10.3390/jcm10122722